Cresaryn
Quick acting oral spray for erectile dysfunction
Cresaryn is on a FDA s505(b)(2) pathway to be the world leading ED product in a US$6.89b market*
FDA
s505(b)(2)
Pathway
10
Years of research development
70m
NanoCelle doses
37
Countries licensed
Patented NanoCelle® delivery platform
with a proven therapeutic for ED
3-7 minutes
Activates 24x faster* than generic form. And twice as fast as next competitor*.
Oro Buccal targeted delivery via nano dispersed carriers
1
Nanoparticle forms
A fat soluble core self assembles inside a water soluble outer layer, carrying the active ingredient.
2
Crosses the oral mucosa
Delivered as an oro buccal spray, absorbed directly through the cheek lining.
3
Bypasses first pass metabolism
Enters circulation without passing through the liver or gastrointestinal tract.
Quick acting ED treatment for a US$6.89b market*
Bypasses first-pass metabolism
Delivered across the oral mucosa, avoiding the liver and GI tract entirely.
Faster absorption
A regulator-recognised absorption-speed claim for the platform itself.
Meaningful market
30–50 million US men and a further estimated 100m globally are estimated to have ED.
Strategic leverage
Control of the 3 major ED drugs with NCV (Tadalafil) having best in market longevity.